N/A N=2,738 Adherence to New Oral Anticoagulation Therapy in Turkey
Atrial Fibrillation
Primary: Compliance of NOACs in Turkish Population — 1342; 1036 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Medtronic CoreValve REDO Study
Aortic Valve Stenosis
Primary: Percentage of MAE Free Subjects — 10 Participants
Phase 3 N=271 Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children
Infections, Meningococcal · Meningococcal Vaccines
Primary: Number of Subjects With Serum Bactericidal Assay, Using Baby Rabbit Complement, Against Neisseria Meningitides Serogroup A, C, W-135, Y (rSBA-MenA, rSBA-MenC…
Phase 4 N=162 The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
Pneumococcal Pneumonia · Influenza
Primary: The Number of Patients With Positive Antibody Response in Serotype 23F of Pneumococcal Antibody. — 63; 59 Participants
N/A N=40 Patient Education Before Orthognathic Surgery
Malocclusion · Anxiety · Micrognathism
Primary: Number of Patients With Clinical Changes During the Postoperative Recovery — 10; 10 participants — p=1.00
Phase 1 N=7 BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Neoplasms
Primary: Individual Time Course Profiles of 14C-radioactivity in Whole Blood and Plasma: Cmax of 14C Labelled Volasertib — 1746; 1150 nmol/L
Phase 3 N=488 Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
Bipolar Disorder · Depression
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Week 6 — -12.6; -15.1; -15.6 score on a scale — p=0.0331
N/A N=320 Hawaii Patient Reward And Incentives to Support Empowerment
Diabetes Mellitus
Primary: Changes in HbA1c From Baseline to the End of Intervention (December 2015) — 0.0660; -0.3440 percentage of glycosylated hemoglobin — p=0.0553
Phase 1 N=33 A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1 — 9.148; 18.18; 25.23; 38.32…
Phase 4 N=2,037 Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
End Stage Renal Disease (ESRD) · Chronic Kidney Disease (CKD) · Hemodialysis
Primary: Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2. — 489; 456…
Phase 2 N=125 Trial of Ibudilast for Methamphetamine Dependence
Methamphetamine Dependence · HIV Infection
Primary: Methamphetamine Use — 9; 10 Participants
N/A N=20 A Novel Method for Capturing the Visual Evoked Potential During Spine Surgery Under Total Intravenous Anesthesia
Evoked Potentials, Visual
Primary: Number of Participants With Presence of VEPs — 18 Participants
Phase 3 N=2,831 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Pregnancy · Respiratory Distress Syndrome · Pregnancy Outcomes
Primary: Neonatal Composite Outcome — 165; 202; 145; 184 Participants — p=0.02
N/A N=51 Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.
Aortic Aneurysm, Abdominal
Primary: Aix@75 — 31.8; 32.5 percentage
Phase 2 N=43 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months